List view / Grid view
We demonstrate the power of waveRAPID in streamlining the kinetic characterisation of large numbers of drug hit compounds, with results comparable to traditional surface plasmon resonance (SPR) and high reproducibility.
Bioanalytical systems have rapidly developed over the past 10 years for lead selection during cell-line development. The advanced technologies for the timely and cost-effective screening of antibodies or vaccines involve consideration of quantitation, kinetics and other critical quality attributes (CQA).
Potential drugs not only need to bind to their targets, they also need to remain bound for a specific amount of time in order to work efficiently.
Harmonising drug-target binding data analytics looks at building a single, integrated software platform for a future pharma research and development digital ecosystem. This webinar, sponsored by PerkinElmer, outlined the fundamentals of a design process where an experimental analytics data workflow was integrated into a more seamlessly interactive digital platform.
Inefficiencies in drug discovery are hard to ignore when despite ever-increasing investment in pharmaceutical research and development, the number of new drugs approved by the US Food and Drug Administration (FDA) remains low.
Sometimes the difference between identifying a partial or super agonist is only the time point at which the binding reaction is measured.
15 January 2018 | By BMG Labtech GmbH
Optimising the receptor binding kinetics of new drugs can have significant benefits, ranging from improved duration of action to enhanced efficacy through the insurmountable antagonism of dynamic physiological systems.Despite this, the kinetics of new receptor ligands are rarely measured early in the drug discovery process, largely because current assays are…
3 April 2017 | By Charles River
This webinar reviews standard neuropathic pain models and readouts and will include fine motor kinematic analysis to highlight gait changes...
IDEA Bio-Medical offers a new feature for spatial detection and characterisation of temporal kinetics of rare events using its advanced HCS system, WiScan® Hermes...
Amorsa Therapeutics' CSO, Michael Palfreyman, discusses how the party drug Ketamine can be used to target NMDA receptors and treat depression...
13 October 2016 | By Charles River Laboratories
Enhances Charles River’s early-stage capabilities in bioanalytical services...
19 July 2016 | By Niamh Louise Marriott
A*STAR and MSD have formed a two year collaboration aimed at improving cellular delivery of macrocyclic peptides...
4 January 2016 | By Victoria White
BPN14770 may be a possible treatment for dementia and Alzheimer’s disease with less potential for side effects than rolipram...
21 September 2015 | By BioTek
The Synergy Neo2 Multi-Mode Reader is designed to provide high temporal resolution in drug target kinetics applications...
19 November 2014 | By Nosopharm
These high-profile experts will help with the quick and safe launch of the preclinical development program for a new class of antibiotics...
